Merck, Daiichi lung cancer therapy rejected in U.S. [Seeking Alpha]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Seeking Alpha
Daiichi Sankyo ( OTCPK:DSKYF ) as a late-line option for a certain type of lung cancer. The companies announced Thursday night that the agency issued a so-called complete response letter (CRL) in response to their biologics license application (BLA) seeking the FDA's accelerated approval for HER3-DXd. The BLA targeted its use in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have undergone two or more prior therapies. However, the regulator hasn't raised concerns over the drug's efficacy or safety as reasons for the rejection. Instead, issues found in a third-party manufacturing facility led to the CRL, the companies said, adding that they would work with the FDA to resolve the concerns and bring HER3-DXd to the market. The drug, also known as patritumab deruxtecan, formed part of a research and commercial collaboration worth up to $22B that Merck ( MRK ) and Daiichi ( OTCPK:DSNKY announced late last year. Recommended For You More
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Arbitration Dispute Between Daiichi Sankyo and Seagen Ends [Yahoo! Finance]Yahoo! Finance
- Arbitration Dispute Between Daiichi Sankyo and Seagen EndsBusiness Wire
- U.S. FDA declines to approve Merck-Daiichi's ‘guided missile' cancer drug [CNBC]CNBC
- FDA issues complete response to Daiichi Sankyo-MSD's BLA for NSCLC [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan [Yahoo! Finance]Yahoo! Finance